Revelation Biosciences, Inc. (REVB)
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
$1.43M
Mr. James M. Rolke
14.00
San Diego, CA
Dec 10, 2013
-0.03
$-33.18
3.40
3.45
272.77%
0.00%
0.37
0.33
0.00
3.40
63.26%
164.24%
Similar stocks (8)
Kiora Pharmaceuticals, Inc.
KPRX
TransCode Therapeutics, Inc.
RNAZ
Sonnet BioTherapeutics Holdings, Inc.
SONN
Quoin Pharmaceuticals, Ltd.
QNRX
ZyVersa Therapeutics, Inc.
ZVSA
Phio Pharmaceuticals Corp.
PHIO
PaxMedica, Inc.
PXMD
Navidea Biopharmaceuticals, Inc.
NAVB
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (8)
Kiora Pharmaceuticals, Inc.
KPRX
TransCode Therapeutics, Inc.
RNAZ
Sonnet BioTherapeutics Holdings, Inc.
SONN
Quoin Pharmaceuticals, Ltd.
QNRX
ZyVersa Therapeutics, Inc.
ZVSA
Phio Pharmaceuticals Corp.
PHIO
PaxMedica, Inc.
PXMD
Navidea Biopharmaceuticals, Inc.
NAVB
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%